At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 210 enrolled
Drug / intervention
Insulin degludec/liraglutide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs
In Brief
A Phase 3 clinical trial evaluating Insulin degludec/liraglutide and Insulin degludec for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 210 participants across 38 sites.
Detailed Summary
This trial is conducted in Asia. The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide and insulin degludec both in combination with metformin in Japanese subjects with type 2 diabetes mellitus inadequately controlled with basal or pre-mix/combination insulin therapy and oral anti-diabetic drugs.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartSep 2016
First PostedSep 2016
Primary CompletionNov 2017
Study CompletionNov 2017
TodayJul 2026
First PostedSep 23, 2016
Enrollment StartSep 21, 2016
Primary CompletionNov 17, 2017
Study CompletionNov 22, 2017
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 9.8 years ago
Interventions
Insulin degludec/liraglutidedrug
Injected s.c. / subcutaneously (under the skin) once daily
Insulin degludecdrug
Injected s.c. / subcutaneously (under the skin) once daily